Merck
Merck
One-line summary: Large-cap US pharma (NYSE: MRK); tracked here as the first-mover in the oral PCSK9 class — its newly-approved Lipfendra is the first oral PCSK9 inhibitor, opening a convenient, price-undercutting entry into the multibillion-dollar cholesterol-lowering market.
What it is
Merck is a diversified large-cap pharmaceutical company. Within this wiki it enters via cardiovascular: Lipfendra, the first oral PCSK9 inhibitor to reach approval — a class previously dominated by injectable antibodies (Amgen's Repatha) and siRNA (Novartis/Alnylam's inclisiran).
Why it matters to stock-market
Merck is the anchor of oral-pcsk9-class-disruption: an oral, near-antibody-potency LDL-lowering drug priced below the incumbents changes the convenience/cost frontier of a large chronic-disease market. First-in-class here is a real edge because adherence and route-of-administration are the binding constraints in cholesterol management.
Key facts
- Lipfendra = first oral PCSK9 approved. john-maraganore in 2026-07-17-podcast-biotech-hangout-episode-189-july-17-2026: "PCSK9 was one of the poster child undruggable targets for a long time and... Merck succeeded." Data is "almost antibody-like PCSK9 reduction" (per yaron-werber), though it carries a food effect and does not yet have cardiovascular-outcomes data (approved on LDL-lowering; "the lower the better" is no longer questioned).
- Priced to undercut. ~$3,800/year, vs roughly $5,000–6,000/year for the injectable antibodies and siRNA products. Approved under Marty Makary's CMPV program. From 2026-07-17-podcast-biotech-hangout-episode-189-july-17-2026.
- Competitive set forming. astrazeneca is following with a macrocyclic-peptide oral PCSK9 (with an ambition to combine it with its oral obesity drug); the incumbent injectable/siRNA market (Amgen Repatha; Novartis/Alnylam inclisiran) is already multibillion-dollar.
Open questions
- Does the food effect / lack of CV-outcomes data cap uptake vs the antibodies near-term?
- How much of the market is net-new (adherence-driven prevention) vs switching from statins/antibodies?
Sources
Related
- oral-pcsk9-class-disruption
- astrazeneca
- john-maraganore — articulated the class read (and is building a once-yearly PCSK9 siRNA at Korro/"Coursera" for prevention)